Ipilimumab Explained

Ipilimumab, sold under the brand name Yervoy, is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.

Cytotoxic T lymphocytes (CTLs) can recognize and destroy cancer cells. However, an inhibitory mechanism interrupts this destruction.[1] Ipilimumab turns off this inhibitory mechanism and boosts the body's immune response against cancer cells.[1]

Ipilimumab was approved by the US Food and Drug Administration (FDA) in March 2011, for the treatment of melanoma, renal cell carcinoma (RCC), colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer (NSCLC), malignant pleural mesothelioma, esophageal cancer.[2] [3] [4] [5] It is undergoing clinical trials for the treatment of bladder cancer[6] and metastatic hormone-refractory prostate cancer.[7]

The concept of using anti-CTLA4 antibodies to treat cancer was first developed by James P. Allison while he was director of the Cancer Research Laboratory at the University of California, Berkeley.[8] [9] Clinical development of anti-CTLA4 was initiated by Medarex, which was later acquired by Bristol-Myers Squibb. For his work in developing ipilimumab, Allison was awarded the Lasker Award in 2015.[10] Allison later was the co-winner of the 2018 Nobel Prize in Physiology or Medicine.[11]

Medical uses

Ipilimumab was approved by the U.S. Food and Drug Administration (FDA) in March 2011, to treat people with late-stage melanoma that has spread or cannot be removed by surgery.[1] [12] [13] It was later approved by the US FDA on October 28, 2015, for stage 3 patients as adjuvant therapy.[14] On February 1, 2012, Health Canada approved ipilimumab for "treatment of unresectable or metastatic melanoma in patients who have failed or do not tolerate other systemic therapy for advanced disease."[15] Ipilimumab was approved in the European Union (EU), for second line treatment of metastatic melanoma in November 2012.[16] [17]

Nivolumab, in combination with ipilimumab is indicated for the treatment of intermediate or poor risk, previously untreated advanced renal cell carcinoma.[18]

Ipilimumab, in combination with nivolumab, is indicated for the treatment of adults and adolescents twelve years and older with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.[19]

Ipilimumab, in combination with nivolumab, is indicated for the treatment of people withhepatocellular carcinoma who have been previously treated with sorafenib.[20]

Ipilimumab, in combination with nivolumab, is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 (≥1%) as determined by an FDA-approved test.[21] [22]

In October 2020, the U.S. FDA approved the combination of nivolumab with ipilimumab for the first-line treatment of adults with malignant pleural mesothelioma that cannot be removed by surgery.[23] This is the first drug regimen approved for mesothelioma in sixteen years and the second FDA-approved systemic therapy for mesothelioma.

Adverse effects

A major drawback of ipilimumab therapy is its association with severe and potentially fatal immunological adverse effects due to T cell activation and proliferation, occurring in ten to twenty percent of patients.[24] Serious adverse effects include stomach pain, bloating, constipation, diarrhea, fever, trouble breathing, and urinating problems. A "risk evaluation and mitigation strategy" informs prescribers of the potential risks.[25] [26]

Between 5.7 and 9.1% of individuals treated with ipilimumab develop checkpoint inhibitor induced colitis.[27]

Individual cases of severe neurologic disorders following ipilimumab have been observed, including acute inflammatory demyelination polyneuropathy and an ascending motor paralysis, and myasthenia gravis.[28]

Interactions

The combination of ipilimumab with either leflunomide or vemurafenib may lead to increased hepatotoxicity.[29] [30] [31] [32]

Systemic corticosteroids should be avoided before starting ipilimumab; however, systemic corticosteroids may be used to treat an immune-related adverse reaction that arises from ipilimumab treatment.[33]

Patients taking anticoagulants with ipilimumab should be monitored due to an increased risk of gastrointestinal bleeding.

Mechanism of action

T lymphocytes can recognize and destroy cancer cells. However, an inhibitory mechanism interrupts this destruction. Ipilimumab turns off this inhibitory mechanism and allows the lymphocytes to continue to destroy cancer cells.[34]

Cancer cells produce antigens, which the immune system can use to identify them. These antigens are recognized by dendritic cells that present the antigens to cytotoxic T lymphocytes (CTLs) in the lymph nodes. The CTLs recognize the cancer cells by those antigens and destroy them. However, along with the antigens, the dendritic cells present an inhibitory signal. That signal binds to a receptor, cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), on the CTL and turns off the cytotoxic reaction. This allows the cancer cells to survive.[34]

Ipilimumab binds to CTLA-4, blocking the inhibitory signal, which allows the CTLs to destroy the cancer cells.[34] [35] [36] [37] [38] [39] [40] In 2014 a study indicated that the antibody works by allowing the patients' T cells to target a greater variety of antigens rather than by increasing the number attacking a single antigen.[41]

Identifying patients most likely to respond

During "cancer immunoediting", tumor cells can produce antigens that provoke a reduced immune response and/or establish an immunosuppressive tumor microenvironment (TME). The latter can arise as a consequence of repeated, ineffective T cell stimulation. This triggers the checkpoint that ipilumumab targets. Many patients do not benefit from treatment, which may be related to reduced mutation load and/or missense point mutation-derived neoantigens.[1] Tumor antigens can either be improperly expressed normal proteins or abnormal proteins with tumor-specific expression. Somatic cancer mutations can produce "nonself" tumor-specific mutant antigens (neoantigens).[42]

Sequencing and epitope prediction algorithms identified neoantigens in mouse tumors that functioned as tumor-specific T cell targets. Neoantigens were recognized by T cells in melanoma patients and were likely the major contributor to positive clinical effects of adoptive cell transfer. Mouse models established that neoantigens were the targets of T cells activated by checkpoint blockade therapy and that synthetic long peptides comprising these neoantigens were effective when administered as vaccines with CTLA-4 and/or PD-1 mAbs. Cancers with higher mutation burdens, and an associated likelihood of expressing neoantigens, appear most likely to respond to checkpoint therapy. In melanoma and certain other cancers, the numbers of mutations and neoantigens correlate with patient response. Increased PD ligand 2 (PD-L2) transcript expression and an immune "cytolytic" gene signature also correlated with neoantigen load and tumor response. CTLA-4 expression was a response indicator, which along with PD-L2 were likely expressed in tumor-infiltrating immune cells. An inflamed TME prior to treatment is also associated with response.

Nearly all neoantigens in one study were patient-specific and most likely reflected mutations that do not directly contribute to tumorigenesis. However, none revealed features or motifs exclusive to responders.

Clinical trial history

In the 2000s, ipilimumab clinical trials were under way on patients with melanoma, renal cell carcinoma, prostate cancers, urothelial carcinoma and ovarian cancer.[43] By 2007, there were two fully human anti CTLA-4[44] monoclonal antibodies in advanced clinical trials. Ipilimumab, which is an IgG1 isotype, and tremelimumab (from Pfizer) which is an IgG2 isotype.[45] [46]

Melanoma

On December 10, 2007, Bristol-Myers Squibb and Medarex released the results of three studies on ipilimumab for melanoma.[47] The three studies tested 487 patients with advanced skin cancer. One of the three studies failed to meet its primary goal of shrinking tumors in at least 10.0% of the study's 155 patients. Side effects included rashes, diarrhea, and hepatitis.

In 2010, a study was presented that showed a median survival of ten months in advanced melanoma patients treated with ipilimumab, compared with 6.4 months for those treated with gp100, an experimental vaccine (n=676), and 10.1 months for those treated with both the vaccine and ipilimumab.[48] The Phase III clinical studies on the drug were controversial for their unconventional use of a control arm (as opposed to using a placebo or standard treatment). Ipilimumab gained FDA approval in March 2011.

Prostate cancer

In 2008/09 Medarex performed a phase I/II dose escalation clinical trial of ipilimumab in metastatic hormone-refractory prostate cancer (HRPC). Some of the patients with advanced prostate cancer had their tumors drastically shrink, promoting further trials.[49]

On June 19, 2009, the Mayo Clinic reported two prostate cancer patients involved in a phase II study using MDX-010 therapy who had been told initially that their condition was inoperable but had their tumors shrunk by the drug such that operation was possible and are now cancer-free as a result.[50] This press report however was criticized as premature and somewhat inaccurate. The clinical trials were still at an early stage and were run alongside other treatments – which could have been the real explanation for the tumor shrinkage.[51] It was too early to say whether ipilimumab made any difference.[52]

In 2016, a phase II study using ipilimumab and nivolumab in AR-V7-expressing metastatic castration-resistant prostate cancer was opened.[53] [54] AR-V7 is an androgen receptor splice variant that can be detected in circulating tumor cells of metastatic prostate cancer patients.[54] [55]

Lung cancer

CHECKMATE-227 [56] tested the combination of nivolumab and ipilimumab in patients with stage IV or recurrent NSCLC without previous treatment.[57] Patients with a PD-L1 expression level of 1% or more were randomized in a 1:1:1 ratio to receive nivolumab plus ipilimumab, nivolumab alone, or chemotherapy. The chemotherapy used was cisplatin or carboplatin, combined with gemcitabine for patient with squamous cell NSCLC, or pemetrexed for patients with nonsquamous disease. The overall survival was 17.1, 15.7 and 14.9 months, respectively. The patients who had a PD-L1 expression level of less than 1% were randomly assigned in a 1:1:1 ratio to receive nivolumab plus ipilimumab, nivolumab plus chemotherapy, or chemotherapy. The OS was 17.2, 15.2 and 12.2 months, respectively.

CHECKMATE-9LA [58] randomized patients with stage IV NSCLC, to nivolumab 360 mg Q3W + ipilimumab 1 mg/kg Q6W + two cycles of chemotherapy or 4 cycles of chemotherapy alone. The chemotherapy used was Cisplatin or Carboplatin combined with Pemetrexed or Paclitaxel. The data were presented in an abstract format and as a lecture during the American Society of Clinical Oncology (ASCO) 2020 annual meeting. Median OS was 15.6 and 10.9 months, in the immunotherapy-chemotherapy and the chemotherapy only groups, respectively.

Urothelial cancer, including cancer of the bladder, urethra, ureters and renal pelvis

A Phase 2 clinical trial entitled First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma was first reported in 2015 [59] Thirty-six patients were treated with chemotherapy, adding ipilimumab after the second 21-day cycle. Though the study did not meet its primary endpoint, a significant expansion of circulating CD4 cells was noted upon addition of ipilimumab, which correlated with improved survival, especially in patients with deleterious somatic DNA damage response mutations.[60]

Combination trials

Advanced melanoma

To increase response rate and reduce adverse reactions, various drug combinations are being tested.

In 2013, a trial was running that compared ipilimumab alone against ipilimumab in combination with nivolumab. The response rate (tumours shrinking by at least 30%) was 58% for the combination, 44% for nivolumab alone, and 19% for ipilimumab alone.[61] This combination gained FDA approval for melanoma in October 2015.

In March 2014, an open-label, randomized, two agent, single center trial started combining ipilimumab with phosphatidylserine-targeting immunotherapy bavituximab for the treatment of advanced melanoma. The number of treated patients in arm A (ipilimumab plus bavituximab) was to be 16, with 8 in arm B (ipilimumab only).[62] The trial was terminated in April 2016 due to low enrollment. Previous, preclinical studies showed that PS targeting antibodies (such as bavituximab) enhance the anti-tumor activity of anti-CTLA-4 and anti-PD-1 antibodies. Tumor growth inhibition correlates with infiltration of immune cells in tumors and induction of adaptive immunity. The combination of these mechanisms promotes strong, localized, anti-tumor responses without the side-effects of systemic immune activation.[63]

Development

Following the 1987 cloning of CTLA-4 in mice,[64] its conservation in humans and similarities with CD28 were soon noticed.[65] CD28 at that time was a recently identified "T cell costimulatory" molecule important for T cell activation.[66] Anti-CTLA-4 blockade, the invention that gave rise to ipilimumab, was conceived by Allison and Krummel along with CTLA-4's inhibitory role in T cell activation.[67] They were able to demonstrate that CTLA-4 signaling in T cells inhibited T cell responses.[68] They then injected intact antibodies and demonstrated that CTLA-4 blockade enhanced T cell responses in mice responding to vaccines and to super antigens.[69] Leach, a new postdoctoral fellow, was tasked by Allison with applying these in tumor models. Antibody-treated mice showed significantly less cancer growth than the controls.[8]

Bluestone and Linsley separately studied the similarities between CD28 and CTLA-4. Bluestone's lab published studies, one together with Krummel and Allison, for in vitro studies of CTLA-4 function.[70] [71] In collaboration with Mark Jenkins, they were able to see effects of anti-CTLA-4 antibodies in vivo in an immunization setting,[72] but did not effectively carry this into tumor biology. Linsley and colleagues had made antibodies against CTLA-4 three years prior to those of Krummel/Allison or Walunas/Bluestone. They concluded that the molecule functioned similarly to CD28 and was a "positive costimulator".[73] They apparently did not pursue CTLA-4 tumor targeting, although BMS licensed the Allison/Leach/Krummel patent through their acquisition of Medarex and the fully humanized antibody MDX010, which later became ipilimumab.

External links

Notes and References

  1. Syn NL, Teng MW, Mok TS, Soo RA . De-novo and acquired resistance to immune checkpoint targeting . The Lancet. Oncology . 18 . 12 . e731–e741 . December 2017 . 29208439 . 10.1016/s1470-2045(17)30607-1 .
  2. Web site: Yervoy . Opdivo . Bristol Myers Squibb . 7 February 2024.
  3. Web site: Drug Approval Package: Yervoy (ipilimumab) Injection NDA #125377 . U.S. Food and Drug Administration (FDA) . 24 December 1999 . 2 October 2020.
  4. Book: Lacroix M . Targeted Therapies in Cancer. 2014. Nova Sciences Publishers. Hauppauge, NY. 978-1-63321-687-7. 2014-07-13. https://web.archive.org/web/20150626172243/https://www.novapublishers.com/catalog/product_info.php?products_id=50994. 2015-06-26. dead.
  5. News: Pollack A . New Class of Drugs Shows More Promise in Treating Cancer . May 29, 2015 . . May 30, 2015 . vanc .
  6. (completed)
  7. (completed)
  8. Leach DR, Krummel MF, Allison JP . Enhancement of antitumor immunity by CTLA-4 blockade . Science . 271 . 5256 . 1734–1736 . March 1996 . 8596936 . 10.1126/science.271.5256.1734 . 7215817 . 1996Sci...271.1734L .
  9. Web site: UC Berkeley Cancer Research Lab » The Story of Yervoy (Ipilimumab). crl.berkeley.edu.
  10. Web site: Deep brain stimulation for Parkinson's disease. Lasker Foundation. The Lasker Foundation.
  11. Web site: The Nobel Prize in Physiology or Medicine 2018 to James P. Allison and Tasuku Honjo . 2018-10-01 . 2018-12-24 . https://web.archive.org/web/20181224054528/https://ki.se/en/news/the-nobel-prize-in-physiology-or-medicine-2018-to-james-p-allison-and-tasuku-honjo . dead .
  12. FDA approves new treatment for a type of late-stage skin cancer . 2011-03-25 . https://web.archive.org/web/20110327063147/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm1193237.htm . 2011-03-27 . U.S. Food and Drug Administration (FDA) . 2011-03-25 . dead .
  13. News: Approval for Drug That Treats Melanoma . Pollack A . 2011-03-25 . . 2011-03-27 . vanc .
  14. FDA approves Yervoy to reduce the risk of melanoma returning after surgery . U.S. Food and Drug Administration (FDA) . 28 October 2015 . 2019-04-08 . https://web.archive.org/web/20151029103812/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm469944.htm . 2015-10-29 . dead .
  15. . First an only treatment to extend survival for people with metastatic melanoma, the most deadly form of skin cancer, approved in Canada . Bristol-Myers Squibb . 7 February 2012 . 2019-04-08 . 2019-04-08 . https://web.archive.org/web/20190408193124/https://www.bms.com/ca/en/media/press-release-listing/2012-02-07-press-release.html . dead .
  16. Bristol-Myers Squibb Receives Positive Decision from National Institute of Health and Clinical Excellence (NICE) for Yervoy (ipilimumab). November 1, 2012. December 17, 2012. February 5, 2017. https://web.archive.org/web/20170205103404/http://news.bms.com/press-release/rd-news/bristol-myers-squibb-receives-positive-decision-national-institute-health-and-. dead.
  17. Maverakis E, Cornelius LA, Bowen GM, Phan T, Patel FB, Fitzmaurice S, He Y, Burrall B, Duong C, Kloxin AM, Sultani H, Wilken R, Martinez SR, Patel F . 6 . Metastatic melanoma - a review of current and future treatment options . Acta Dermato-Venereologica . 95 . 5 . 516–524 . May 2015 . 25520039 . 10.2340/00015555-2035 . free .
  18. Web site: FDA approves nivolumab plus ipilimumab combination for intermediate or poor-risk advanced renal cell carcinoma . U.S. Food and Drug Administration (FDA) . 16 April 2018 . 2 October 2020.
  19. Web site: FDA grants accelerated approval to ipilimumab for MSI-H or dMMR metastatic colorectal cancer . U.S. Food and Drug Administration (FDA) . 10 July 2018 . 2 October 2020.
  20. Web site: FDA grants accelerated approval to nivolumab and ipilimumab combination for hepatocellular carcinoma . U.S. Food and Drug Administration (FDA) . 10 March 2020 . 2 October 2020.
  21. Web site: FDA approves nivolumab plus ipilimumab for first-line mNSCLC (PD-L1 tumor expression ≥1%) . U.S. Food and Drug Administration (FDA) . 15 May 2020 . 2 October 2020.
  22. Web site: FDA approves nivolumab plus ipilimumab and chemotherapy for first-line treatment of metastatic NSCLC . U.S. Food and Drug Administration (FDA) . 26 May 2020 . 2 October 2020.
  23. FDA Approves Drug Combination for Treating Mesothelioma . U.S. Food and Drug Administration (FDA) . 2 October 2020 . 2 October 2020.
  24. Johnson DB, Peng C, Sosman JA . Nivolumab in melanoma: latest evidence and clinical potential . Therapeutic Advances in Medical Oncology . 7 . 2 . 97–106 . March 2015 . 25755682 . 4346215 . 10.1177/1758834014567469 .
  25. Drugs.com: Yervoy
  26. Web site: FDA Rubber-Stamps Bristol-Myers Squibb's Melanoma mAb . 2011-03-28 . Genetic Engineering & Biotechnology News . 2011-03-28 . 2011-04-01 . https://web.archive.org/web/20110401210253/http://www.genengnews.com/gen-news-highlights/fda-rubber-stamps-bristol-myers-squibb-s-melanoma-mab/81244882/ . dead .
  27. Bellaguarda E, Hanauer S . Checkpoint Inhibitor-Induced Colitis . The American Journal of Gastroenterology . 115 . 2 . 202–210 . February 2020 . 31922959 . 10.14309/ajg.0000000000000497 . 210150535 .
  28. Web site: Two Cases of Myasthenia Gravis Seen With Ipilimumab . 2014-04-29 .
  29. Web site: Arava (leflunomide) [package insert]]. Australia: Sanofi-Aventis, July 2014. 2 November 2014. 2 November 2014. https://web.archive.org/web/20141102230854/http://products.sanofi.com.au/aus_pi_arava.pdf. dead.
  30. Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J . Hepatotoxicity with combination of vemurafenib and ipilimumab . The New England Journal of Medicine . 368 . 14 . 1365–1366 . April 2013 . 23550685 . 10.1056/NEJMc1302338 . free .
  31. Web site: Zelboraf (vemurafenib) [package insert]]. South San Francisco, CA: Genentech USA, Inc.; March 2013. 29 October 2014.
  32. Web site: Yervoy (ipilimumab) [package insert] ]. Princeton, NJ: Bristol-Myers Squibb Company; Dec 2013 . 29 October 2014 . dead . https://web.archive.org/web/20150206103033/http://packageinserts.bms.com/pi/pi_yervoy.pdf . 6 February 2015 .
  33. Web site: Yervoy Annex I: Summary of Product Characteristics. 2 November 2014. 20 December 2014. https://web.archive.org/web/20141220131813/http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002213/WC500109299.pdf. dead.
  34. Ribas A . Tumor immunotherapy directed at PD-1 . The New England Journal of Medicine . 366 . 26 . 2517–2519 . June 2012 . 22658126 . 10.1056/nejme1205943 .
  35. Tarhini AA, Iqbal F . CTLA-4 blockade: therapeutic potential in cancer treatments . OncoTargets and Therapy . 3 . 15–25 . June 2010 . 20616954 . 2895779 . 10.2147/ott.s4833 . free .
  36. Robert C, Ghiringhelli F . What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma? . The Oncologist . 14 . 8 . 848–861 . August 2009 . 19648604 . 10.1634/theoncologist.2009-0028 . free .
  37. Book: Wilkes GM, Barton-Burke M . 2010 oncology nursing drug handbook. 30 March 2011. 11 December 2009. Jones & Bartlett Learning. 978-0-7637-8124-8. 1–.
  38. Book: Reddy LH, Couvreur P . Macromolecular Anticancer Therapeutics. 30 March 2011. 1 June 2009. Springer. 978-1-4419-0506-2. 522–.
  39. Book: An Z . Therapeutic Monoclonal Antibodies: From Bench to Clinic. 30 March 2011. 8 September 2009. John Wiley and Sons. 978-0-470-11791-0. 134–.
  40. Book: Blum R, Scholz M . Invasion of the Prostate Snatchers: No More Unnecessary Biopsies, Radical Treatment Or Loss of Sexual Potency. registration. 30 March 2011. 24 August 2010. Other Press, LLC. 978-1-59051-342-2. 227–.
  41. Cancer immunotherapy expands T cell attack. Science. 1463. 345. 6203. 10.1126/science.345.6203.1463-c. Colmone AC . 2014. 2014Sci...345Q1463C.
  42. Gubin MM, Schreiber RD . CANCER. The odds of immunotherapy success . Science . 350 . 6257 . 158–159 . October 2015 . 26450194 . 10.1126/science.aad4140 . 206643238 . 2015Sci...350..158G .
  43. Sharma P, Allison JP . The future of immune checkpoint therapy . Science . 348 . 6230 . 56–61 . April 2015 . 25838373 . 10.1126/science.aaa8172 . 4608450 . 2015Sci...348...56S .
  44. Web site: CTLA-4 strategies: Abatacept / Belatacept . healthvalue.net . 2009-06-24 . 2008-12-05 . https://web.archive.org/web/20081205034856/http://www.healthvalue.net/ctlaigenglish.html . dead .
  45. Tomillero A, Moral MA . Gateways to clinical trials . Methods and Findings in Experimental and Clinical Pharmacology . 30 . 8 . 643–672 . October 2008 . 19088949 . 10.1358/mf.2008.30.5.1236622 .
  46. Poust J . Targeting metastatic melanoma . American Journal of Health-System Pharmacy . 65 . 24 Suppl 9 . S9–S15 . December 2008 . 19052265 . 10.2146/ajhp080461 . 207291355 .
  47. Web site: Top-Line Data Available from Three Ipilimumab Pivotal Trials in Patients with Advanced Metastatic Melanoma . 2007-12-10 . Medarex, Inc. . 2009-06-24 . dead . https://web.archive.org/web/20081020042102/https://www.bms.com/ . October 20, 2008 .
  48. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ . 6 . Improved survival with ipilimumab in patients with metastatic melanoma . The New England Journal of Medicine . 363 . 8 . 711–723 . August 2010 . 20525992 . 3549297 . 10.1056/NEJMoa1003466 .
  49. News: 'Surprise' prostate result probed . 2009-06-19 . BBC News . 2009-06-24.
  50. Web site: Mayo Researchers: Dramatic Outcomes in Prostate Cancer Study . 2009-06-01 . Mayo Clinic . 2009-06-24 . 2009-06-23 . https://web.archive.org/web/20090623054534/http://www.mayoclinic.org/news2009-rst/5318.html . dead .
  51. Web site: New Therapy May Fight Prostate Cancer . Boyles S . 2009-06-19 . WebMD . 2009-06-24.
  52. Web site: Medarex, Ipilimumab, Prostate Cancer, And Reality . Lowe D . Derek Lowe (chemist) . 2009-06-23 . . 2016-08-11.
  53. Web site: Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7 - Full Text View - ClinicalTrials.gov. clinicaltrials.gov. 2016-02-27.
  54. Silberstein JL, Taylor MN, Antonarakis ES . Novel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate Cancer . Current Urology Reports . 17 . 4 . 29 . April 2016 . 26902623 . 4888068 . 10.1007/s11934-016-0584-4 .
  55. Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J . 6 . AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer . The New England Journal of Medicine . 371 . 11 . 1028–1038 . September 2014 . 25184630 . 4201502 . 10.1056/NEJMoa1315815 .
  56. Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora Jimenez E, Sakai H, Albert I, Vergnenegre A, Peters S, Syrigos K, Barlesi F, Reck M, Borghaei H, Brahmer JR, O'Byrne KJ, Geese WJ, Bhagavatheeswaran P, Rabindran SK, Kasinathan RS, Nathan FE, Ramalingam SS . 6 . Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer . The New England Journal of Medicine . 381 . 21 . 2020–2031 . November 2019 . 31562796 . 10.1056/NEJMoa1910231 . free .
  57. Nasser NJ, Gorenberg M, Agbarya A . First line Immunotherapy for Non-Small Cell Lung Cancer . Pharmaceuticals . 13 . 11 . 373 . November 2020 . 33171686 . 7695295 . 10.3390/ph13110373 . free .
  58. Reck M, Ciuleanu TE, Dols MC, Schenker M, Zurawski B, Menezes J, Richardet E, Bennouna J, Felip E, Juan-Vidal O, Alexandru A . 6 . 2020-05-20. Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA.. Journal of Clinical Oncology. 38. 15_suppl. 9501. 10.1200/JCO.2020.38.15_suppl.9501. 219780650. 0732-183X.
  59. Web site: Impact of gemcitabine + cisplatin + ipilimumab on circulating immune cells in patients (pts) with metastatic urothelial cancer (mUC). - 2015 ASCO Annual Meeting - Abstracts - Meeting Library. 2016-03-07. 2016-03-08. https://web.archive.org/web/20160308003335/http://meetinglibrary.asco.org/content/153523-156. dead.
  60. Galsky MD, Wang H, Hahn NM, Twardowski P, Pal SK, Albany C, Fleming MT, Starodub A, Hauke RJ, Yu M, Zhao Q, Sonpavde G, Donovan MJ, Patel VG, Sfakianos JP, Domingo-Domenech J, Oh WK, Akers N, Losic B, Gnjatic S, Schadt EE, Chen R, Kim-Schulze S, Bhardwaj N, Uzilov AV . 6 . Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes . European Urology . 73 . 5 . 751–759 . May 2018 . 29248319 . 10.1016/j.eururo.2017.12.001 .
  61. Web site: Immunotherapy drug combo could combat melanoma. pmhdev. PubMed Health.
  62. Web site: Peregrine Pharmaceuticals Announces Initiation of an Investigator-Sponsored Trial Combining Its Immunotherapy Bavituximab and Ipilimumab (Yervoy) in Advanced Melanoma. Peregrine Pharmaceuticals, Inc. 2014-05-20. https://web.archive.org/web/20151014212117/http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=841892. 2015-10-14. dead.
  63. News: Data Presented at AACR Support Potential of Peregrine's PS-Targeting Immunotherapy Bavituximab to Enhance Anti-Tumor and Immune-Stimulating Effects of Anti-CTLA-4 and Anti-PD-1 Treatments in Models of Melanoma and Colon Cancer . https://web.archive.org/web/20140521031338/http://www.reuters.com/article/2014/04/09/idUSnMKWDgVlta+1e8+MKW20140409 . dead . 2014-05-21 . 2014-04-09 . Reuters . 2014-04-09.
  64. Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG, Golstein P . A new member of the immunoglobulin superfamily--CTLA-4 . Nature . 328 . 6127 . 267–270 . Jul 1987 . 3496540 . 10.1038/328267a0 . 4316396 . 1987Natur.328..267B .
  65. Harper K, Balzano C, Rouvier E, Mattéi MG, Luciani MF, Golstein P . CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location . Journal of Immunology . 147 . 3 . 1037–1044 . August 1991 . 1713603 . 10.4049/jimmunol.147.3.1037 . 25735978 . free .
  66. Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP . CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones . Nature . 356 . 6370 . 607–609 . April 1992 . 1313950 . 10.1038/356607a0 . 4333730 . 1992Natur.356..607H .
  67. Krummel, M.F. (1995). Identification and Characterization of a CTLA-4 Dependent Regulatory Mechanism for T Cell Activation (University of California, Berkeley).
  68. Krummel MF, Allison JP . CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation . The Journal of Experimental Medicine . 182 . 2 . 459–465 . August 1995 . 7543139 . 2192127 . 10.1084/jem.182.2.459 .
  69. Krummel MF, Sullivan TJ, Allison JP . Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo . International Immunology . 8 . 4 . 519–523 . April 1996 . 8671638 . 10.1093/intimm/8.4.519 . free .
  70. Walunas TL, Bakker CY, Bluestone JA . CTLA-4 ligation blocks CD28-dependent T cell activation . The Journal of Experimental Medicine . 183 . 6 . 2541–2550 . June 1996 . 8676075 . 2192609 . 10.1084/jem.183.6.2541 .
  71. Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, Thompson CB, Bluestone JA . 6 . CTLA-4 can function as a negative regulator of T cell activation . Immunity . 1 . 5 . 405–413 . August 1994 . 7882171 . 10.1016/1074-7613(94)90071-x .
  72. Kearney ER, Walunas TL, Karr RW, Morton PA, Loh DY, Bluestone JA, Jenkins MK . Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4 . Journal of Immunology . 155 . 3 . 1032–1036 . August 1995 . 7543510 . 10.4049/jimmunol.155.3.1032 . 23874889 . free .
  73. Linsley PS, Greene JL, Tan P, Bradshaw J, Ledbetter JA, Anasetti C, Damle NK . Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes . The Journal of Experimental Medicine . 176 . 6 . 1595–1604 . December 1992 . 1334116 . 2119471 . 10.1084/jem.176.6.1595 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Ipilimumab".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.